全文获取类型
收费全文 | 1367篇 |
免费 | 42篇 |
专业分类
电工技术 | 4篇 |
化学工业 | 177篇 |
金属工艺 | 20篇 |
机械仪表 | 15篇 |
建筑科学 | 16篇 |
矿业工程 | 1篇 |
能源动力 | 17篇 |
轻工业 | 74篇 |
水利工程 | 15篇 |
石油天然气 | 1篇 |
无线电 | 60篇 |
一般工业技术 | 110篇 |
冶金工业 | 817篇 |
原子能技术 | 11篇 |
自动化技术 | 71篇 |
出版年
2022年 | 13篇 |
2021年 | 27篇 |
2020年 | 14篇 |
2019年 | 27篇 |
2018年 | 24篇 |
2017年 | 12篇 |
2016年 | 17篇 |
2015年 | 16篇 |
2014年 | 32篇 |
2013年 | 39篇 |
2012年 | 38篇 |
2011年 | 30篇 |
2010年 | 22篇 |
2009年 | 24篇 |
2008年 | 24篇 |
2007年 | 28篇 |
2006年 | 17篇 |
2005年 | 14篇 |
2004年 | 20篇 |
2003年 | 15篇 |
2002年 | 8篇 |
2001年 | 8篇 |
2000年 | 12篇 |
1999年 | 27篇 |
1998年 | 231篇 |
1997年 | 143篇 |
1996年 | 96篇 |
1995年 | 59篇 |
1994年 | 45篇 |
1993年 | 52篇 |
1992年 | 11篇 |
1991年 | 12篇 |
1990年 | 20篇 |
1989年 | 28篇 |
1988年 | 19篇 |
1987年 | 20篇 |
1986年 | 13篇 |
1985年 | 13篇 |
1984年 | 7篇 |
1983年 | 12篇 |
1982年 | 10篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1978年 | 3篇 |
1977年 | 30篇 |
1976年 | 43篇 |
1975年 | 2篇 |
1973年 | 4篇 |
1965年 | 1篇 |
1955年 | 3篇 |
排序方式: 共有1409条查询结果,搜索用时 31 毫秒
1.
2.
3.
E Arvat R Giordano J Ramunni G Arnaldi A Colao R Deghenghi G Lombardi F Mantero F Camanni E Ghigo 《Canadian Metallurgical Quarterly》1998,83(12):4207-4211
We previously reported that in Cushing's disease (CD) the ACTH- and cortisol (F)-releasing activity of Hexarelin (HEX), a GH secretagogue, is exaggerated with respect to that in normal subjects and is higher than that of human CRH (hCRH), but it is absent in Cushing's syndrome. Our aim was to extend the study about the effects of HEX (2.0 microg/kg, iv) on ACTH and F secretion in 21 patients with CD (3 men and 18 women, 16-68 yr old). Based on magnetic resonance imaging, 15 CD patients had pituitary microadenoma, and 6 had macroadenoma. The results in CD patients were compared with those in 27 normal age-matched controls (NS; 10 men and 17 women, 24-69 yr old). Basal ACTH and F levels in CD were similar in patients with microadenom (mean+/-SEM, 78.3+/-7.2 pg/mL and 237.1+/-23.6 microg/L, respectively) and macroadenoma (57.4+/-9.0 pg/mL and 196.9+/-20.1 microg/L, respectively) and were higher (P < 0.001) than those in NS (17.7+/-2.0 pg/mL and 115.3+/-6.7 microg/L, respectively). In microadenoma CD patients, HEX induced marked ACTH and F increases (delta peak, mean+/-SEM: 261.2+/-77.6 pg/mL and 226.1+/-87.2 microg/L, respectively), which were higher (P < 0.04) than those induced by hCRH (45.6+/-16.9 pg/mL and 84.6+/-25.7 microg/L, respectively). Moreover, in microadenoma CD patients, the ACTH and F responses to HEX were higher (P < 0.001) than those in NS (18.5+/-4.0 pg/mL and 36.1+/-6.8 microg/L, respectively). In macroadenoma CD patients, HEX induced a slight, but significant increase (P < 0.02) in ACTH and F levels (33.9+/-18.0 pg/mL and 89.6+/-34.3 microg/L, respectively), which was not significantly different from that elicited by hCRH (20.0+/-7.0 pg/mL and 54.8+/-21.3 microg/L, respectively). In macroadenoma CD patients, the ACTH and F responses to HEX and hCRH were, in turn, similar to those in NS. In conclusion, our findings demonstrate that the ACTH and F hyperresponsiveness to HEX is present in Cushing's disease with micro-, but not macro- ACTH-secreting pituitary adenoma. This finding agrees with other evidence pointing toward differences in the hormonal behavior between micro- and ACTH-secreting pituitary macroadenomas. 相似文献
4.
WR Volger RS Weiner JO Moore GA Omura AA Bartolucci M Stagg 《Canadian Metallurgical Quarterly》1995,9(9):1456-1460
A phase III clinical trial was designed to determine if more intensive induction and consolidation therapy for acute myeloblastic leukemia increases the remission rate and prolongs survival. A minor objective was to determine if the use of non-cross resistant drugs was more effective than the same drugs used for induction. Patients with untreated leukemia between the ages of 15 and 50 were given daunorubicin 45 mg/m2 for the first 3 days of a 10-day continuous infusion of cytosine arabinoside, initially at a dose of 2000 mg/m2 but reduced to 100 mg/m2 because of toxicity. Those under 36 achieving a complete remission and with an histocompatible donor were assigned to a transplant arm. The rest were randomized to receive one of three consolidation arms: A, cytosine arabinoside, 200 mg/m2 daily for 7 days and daunorubicin 45 mg/m2 daily for 3 days for three courses; B, one course as in Arm A followed by amsacrine, 120 mg/m2 daily for 5 days followed by a 5-day continuous infusion of azacytidine, 150 mg/m2/day; C, thioguanine and cytosine arabinoside, 100 mg/m2 every 12 h and daunorubicin 10 mg/m2 daily for 5 days for three courses followed by four maintenance courses of cytosine arabinoside, 100 mg/m2 daily for 5 days and daunorubicin, 45 mg/m2 for 2 days every 13 weeks. From 1981 to 1986, 398 eligible patients were enrolled and 219 achieved a complete remission. The initial induction dose of cytosine arabinoside was reduced after five of 29 patients exhibited fatal gastrointestinal toxicity. Only 11 patients were assigned to the transplant arm. There were no significant differences in the consolidation arms. The 5 year disease-free survivals were 38, 31 and 27% in arms A, B, and C respectively. Intensive consolidation therapy with the same or different drugs used in induction was as effective as lower dose consolidation followed by maintenance therapy. 相似文献
5.
6.
G Giordano 《Canadian Metallurgical Quarterly》1996,67(3):327-334
Thyroid nodules are among the most common clinical problems in endocrinology. Among several factors responsible for the development of goiter, circulating TSH plays a major role because of its direct growth-promoting effects on the thyroid cells; moreover TSH may enhance the effects of other local growth factors which act in a paracrine mode in the thyroid gland. In addition, autoimmune thyroiditis can clinically appear as thyroid nodules frequently with the functional aspect of a subclinical hypothyroidism. For these reasons a therapeutical approach based on the thyroxine suppression of TSH secretion has become largely used by 1970s and is correctly employed in 75% of the patients with thyroid nodules whose biopsies result benign. 相似文献
7.
All over the world there are enormous unexploited renewable energy reserves (hydro, geothermic, solar, wind, etc.). Most originate far from the location of the users, so their exploitation would greatly benefit from the disclosure of new, more economical, and technically feasible transmission systems.A possible alternative to electricity is the use of hydrogen as a medium for transportation of energy. This work proposes a chemical closed-loop cycle based upon catalytic reversible reactions as a means to transmit hydrogen. A real example for the application of the proposed system for transportation of secondary energy was considered. In particular, choosing a large hydro-electric source as reference, a comparison was made between costs and efficiencies in transferring energy as hydrogen (in its different forms) over long distances, with respect to transportation of the same energy as electricity. 相似文献
8.
9.
10.
H Nakamine AS Masih WC Chan WG Sanger JO Armitage DD Weisenburger 《Canadian Metallurgical Quarterly》1993,10(1-2):79-88
Southern blot analysis was performed with a panel of DNA probes to detect rearrangements of c-myc, bcl-1, bcl-2 and bcl-3 in 14 cases of B-cell non-Hodgkin's lymphoma (NHL) with a clonal cytogenetic rearrangement involving the chromosome 14q32 locus and no known donor chromosome [t(14;?)(q32;?)]. In our experience, 21% of all chromosomal abnormalities involving the 14q32 locus in B-cell NHL are of this type. We found oncogene rearrangements in five of the 14 cases: bcl-1 rearrangement on one mantle zone lymphoma, bcl-2 rearrangements in two follicular lymphomas, and c-myc rearrangements in two small noncleaved cell lymphomas. We conclude that a 14q32+ abnormality of unknown origin is a relatively frequent karyotypic finding in B-cell NHL. In one third of the cases, known oncogenes that have been previously described in reciprocal translocations involving the immunoglobulin heavy chain locus were shown to be involved in the 14q32+ abnormality. The translocations in the other cases are likely to have involved one of the above oncogenes with breakpoints not revealed by the probes employed, other known oncogenes, or oncogenes that have not yet been identified. 相似文献